CYCC — Cyclacel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.35m
- -$1.03m
- $0.42m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -7.83 | -8.45 | -18.9 | -21.2 | -22.6 |
Depreciation | |||||
Non-Cash Items | 0.357 | 0.337 | 1.33 | 1.55 | 1.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.99 | 0.154 | -1.02 | -1.21 | 5.01 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Cash from Operating Activities | -9.45 | -7.93 | -18.5 | -20.8 | -16.1 |
Capital Expenditures | -0.01 | -0.096 | -0.027 | -0.007 | -0.006 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.038 | 0 | — | — | — |
Sale of Fixed Assets | |||||
Cash from Investing Activities | 0.028 | -0.096 | -0.027 | -0.007 | -0.006 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 3.85 | 29.5 | 21.7 | 3 | 0.848 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -5.62 | 21.5 | 3.15 | -18.2 | -15 |